KRAS Mutations in Advanced Nonsquamous Non–Small-Cell Lung Cancer Patients Treated with First-Line Platinum-Based Chemotherapy Have No Predictive Value-Reference-Cited by-同舟云学术

KRAS Mutations in Advanced Nonsquamous Non–Small-Cell Lung Cancer Patients Treated with First-Line Platinum-Based Chemotherapy Have No Predictive Value

Published:2013-09 Issue:9 Volume:8 Page:1190-1195
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Mellema Wouter W.,Dingemans Anne-Marie C.,Thunnissen Erik,Snijders Peter J.F.,Derks Jules,Heideman Daniëlle A.M.,Van Suylen Robertjan,Smit Egbert F.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference22 articles.

1. The hallmarks of cancer;Hanahan;Cell,2000

2. Hallmarks of cancer: the next generation;Hanahan;Cell,2011

3. RAS oncogenes: weaving a tumorigenic web;Pylayeva-Gupta;Nat Rev Cancer,2011

4. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung;Slebos;N Engl J Med,1990

5. K-ras as a target for lung cancer therapy;Adjei;J Thorac Oncol,2008

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Additional impact of genetic ancestry over race/ethnicity to prevalence of KRAS mutations and allele-specific subtypes in non-small cell lung cancer;Human Genetics and Genomics Advances;2024-07

2. Assessing the prognostic value of KRAS mutation combined with tumor size in stage I-II non-small cell lung cancer: a retrospective analysis;Frontiers in Oncology;2024-05-31

3. Equalizing prognostic disparities in stage III KRAS-mutant NSCLC: addition of durvalumab to combined chemoradiotherapy improves survival;2024-03-22

4. KRASmutations in combination with primary tumor size are not associated with a worse prognosis in early Non-Small Cell Lung Cancer;2023-05-05

5. Correlation between KRAS mutation subtypes and prognosis in Chinese advanced non‐squamous non‐small cell lung cancer patients;Cancer Medicine;2023-05-04